Literature DB >> 11134112

Comparison of hypocalcemic hypercalciuria between patients with idiopathic hypoparathyroidism and those with gain-of-function mutations in the calcium-sensing receptor: is it possible to differentiate the two disorders?

M Yamamoto1, T Akatsu, T Nagase, E Ogata.   

Abstract

Gain-of-function mutations in the calcium ion-sensing receptor (CaR) cause hypocalcemia with low PTH levels. It is stated that patients with activating CaR mutations generally show milder degree of hypocalcemia before treatment and more profound hypercalciuria during treatment than those with idiopathic hypoparathyroidism (IHP). To test this validity we analyzed the data of serum and urinary calcium collected from 85 patients with IHP and 15 with activating CaR mutations. The mean (+/-SEM) serum calcium concentration before treatment was significantly higher (P: < 0.001) in patients with activating CaR mutations (1.76 +/- 0.05 mmol/L; n = 15) than in those with IHP (1.41 +/- 0.03; n = 58), but there was a substantial overlap in the range of hypocalcemia between the two groups (1.25-2. 05 vs. 0.90-1.95). The mean urinary calcium/creatinine ratio (Ca/Cr) in patients with activating CaR mutations before treatment (0.362 +/- 0.045 mmol/mmol; n = 9) was almost equal to that in normocalcemic controls (0.331 +/- 0.022; n = 56) and markedly higher (P: < 0.001) than in patients with IHP (0.093 +/- 0.008; n = 57). The overlap of pretreatment urinary Ca/Cr between the 2 disorders was relatively small; subnormal urinary Ca/Cr was observed in only 1 of 9 patients with CaR mutations and in the majority (49 of 57) of patients with IHP. In contrast to pretreatment findings, the degree of hypercalciuria during treatment was not different between the 2 disorders. The data points of urinary Ca/Cr plotted as a function of the serum calcium concentration were not separable between patients with CaR mutations (n = 8) and those with IHP (n = 40). Comparison of urinary Ca/Cr between 2 patients with a CaR mutation and 7 with IHP over a wide range of serum calcium concentrations measured during 4-8 yr of treatment also indicated that the 2 disorders were inseparable. These results suggested that inappropriately normal urinary Ca/Cr in patients with untreated hypocalcemia, mostly of mild degree, might be a better biochemical clue than the development of severe hypercalciuria during treatment to suspect gain-of-function mutations in the CaR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11134112     DOI: 10.1210/jcem.85.12.7035

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

Review 1.  Kidney stone disease.

Authors:  Fredric L Coe; Andrew Evan; Elaine Worcester
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 2.  International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function.

Authors:  Katie Leach; Fadil M Hannan; Tracy M Josephs; Andrew N Keller; Thor C Møller; Donald T Ward; Enikö Kallay; Rebecca S Mason; Rajesh V Thakker; Daniela Riccardi; Arthur D Conigrave; Hans Bräuner-Osborne
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

3.  Calcium-sensing receptor sequencing in 21 patients with idiopathic or familial parathyroid disorder: pitfalls and characterization of a novel I32 V loss-of-function mutation.

Authors:  Auryan Szalat; Michal Shahar; Shoshana Shpitzen; Boaz Nachmias; Gabriel Munter; David Gillis; Ronen Durst; Dror Mevorach; Eran Leitersdorf; Vardiella Meiner; Haim Rosen
Journal:  Endocrine       Date:  2014-08-05       Impact factor: 3.633

Review 4.  Genetic causes of hypercalciuric nephrolithiasis.

Authors:  Michael J Stechman; Nellie Y Loh; Rajesh V Thakker
Journal:  Pediatr Nephrol       Date:  2008-04-30       Impact factor: 3.714

5.  A novel gain-of-function mutation (F821L) in the transmembrane domain of calcium-sensing receptor is a cause of severe sporadic hypoparathyroidism.

Authors:  Masaaki Shiohara; Tetsuo Mori; Bai Mei; Edward M Brown; Tomoyuki Watanabe; Toshiyuki Yasuda
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

Review 6.  Physiology and pathophysiology of the calcium-sensing receptor in the kidney.

Authors:  Daniela Riccardi; Edward M Brown
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-18

7.  Ultrasound is superior to computed tomography for assessment of medullary nephrocalcinosis in hypoparathyroidism.

Authors:  Alison M Boyce; Thomas H Shawker; Suvimol C Hill; Peter L Choyke; Michael C Hill; Robert James; Nancy A Yovetich; Michael T Collins; Rachel I Gafni
Journal:  J Clin Endocrinol Metab       Date:  2013-01-24       Impact factor: 5.958

8.  Novel Mutation in the CASR Gene (p.Leu123Ser) in a Case of Autosomal Dominant Hypocalcemia.

Authors:  Joana Regala; Branca Cavaco; Rita Domingues; Catarina Limbert; Lurdes Lopes
Journal:  J Pediatr Genet       Date:  2015-03

9.  Successful treatment of postsurgical hypoparathyroidism by intramuscular injection of vitamin D3 in a patient associated with malabsorption syndrome due to multiple abdominal surgeries.

Authors:  Toshiro Seki; Masaaki Yamamoto; Rina Ohwada; Kazue Takano; Masahiko Kure; Hidenori Sekine; Yoshiya Katsura; Kanji Sato
Journal:  J Bone Miner Metab       Date:  2009-08-06       Impact factor: 2.626

10.  Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization.

Authors:  Dong Li; Evan E Opas; Florin Tuluc; Daniel L Metzger; Cuiping Hou; Hakon Hakonarson; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2014-05-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.